ESMO 2025: Paradigm Shift in Breast Cancer Treatment

At the ESMO 2025 Presidential Symposium, Professor Charles Geyer from the University of Pittsburgh Hillman Cancer Center presented the results of the phase III DESTINY-Breast05 trial. Together with DESTINY-Breast11, the data highlight the evolving role of antibody–drug conjugates—not only as potent treatment options in advanced disease, but also as potential new standards of care in early breast cancer. In this MEDtalk, Professor Geyer discusses the key findings from DESTINY-Breast05 together with the KATHERINE Trial.